ABSTRACT
Opioids are a mainstay of pain management but can induce unwanted effects, including analgesic tolerance and paradoxical hyperalgesia, either of which leads to increased pain. Clinically, however, the relationship between these two phenomena remains elusive. By evaluating changes in mechanical nociceptive threshold in male rats, we found that in contrast to a purely analgesic control response to a single subcutaneous administration of fentanyl (25 µg/kg), in rats subjected to inflammatory pain 2 weeks previously (Day0), the same test dose (D13) induced a bi-phasic response: initial decreased analgesia (tolerance) followed by hyperalgesia lasting several hours. Both the tolerance and hyperalgesia were further enhanced in rats that had additionally received fentanyl on D0. The dose-response profiles (5 fg to 50 µg/kg) of pain- and opioid-experienced rats were very different from pain/drug-naive rats. At ultra-low fentanyl doses (<5 ng/kg and <500 ng/kg for naïve control and pain/drug-experienced rats, respectively), solely hyperalgesia was observed in all cases. At higher doses, which now produced analgesia alone in naive rats, reduced analgesia (tolerance) coupled with hyperalgesia occurred in pain/fentanyl-experienced rats, with both phases increasing with dose. Transcriptomic and pharmacological data revealed that an overactivation of the spinal N-methyl-D-aspartate receptor-inducible NO synthase cascade plays a critical role in both acute tolerance and hyperalgesia, and together with the finding that the magnitudes of analgesia and associated hyperalgesia are negatively correlated, is indicative of closely related phenomena. Finally, a polyamine deficient diet prevented inducible NO synthase transcript upregulation, restored fentanyl's analgesic efficacy and suppressed the emergence of hyperalgesia.
Subject(s)
Fentanyl , Hyperalgesia , Analgesics/pharmacology , Analgesics, Opioid/pharmacology , Animals , Diet , Fentanyl/pharmacology , Hyperalgesia/chemically induced , Hyperalgesia/drug therapy , Hyperalgesia/prevention & control , Male , Polyamines/adverse effects , Rats , Rats, Sprague-DawleyABSTRACT
Neuropeptide FF receptors (NPFF1R and NPFF2R) and their endogenous ligand neuropeptide FF have been shown previously to display antiopioid properties and to play a critical role in the adverse effects associated with chronic administrations of opiates including the development of opioid-induced hyperalgesia and analgesic tolerance. In this work, we sought to identify novel NPFF receptors ligands by focusing our interest in a series of heterocycles as rigidified nonpeptide NPFF receptor ligands, starting from already described aminoguanidine hydrazones (AGHs). Binding experiments and functional assays highlighted AGH 1n and its rigidified analogue 2-amino-dihydropyrimidine 22e for in vivo experiments. As shown earlier with the prototypical dipeptide antagonist RF9, both 1n and 22e reduced significantly the long lasting fentanyl-induced hyperalgesia in rodents. Altogether these data indicate that AGH rigidification maintains nanomolar affinities for both NPFF receptors, while improving antagonist character toward NPFF1R.
Subject(s)
Guanidines/pharmacology , Hydrazones/pharmacology , Hyperalgesia/drug therapy , Nociception/drug effects , Receptors, Neuropeptide/antagonists & inhibitors , Analgesics, Opioid/adverse effects , Animals , Drug Tolerance , Hyperalgesia/chemically induced , Male , Mice , Rats , Rats, Sprague-Dawley , Structure-Activity RelationshipABSTRACT
Although opiates represent the most effective analgesics, their use in chronic treatments is associated with numerous side effects including the development of pain hypersensitivity and analgesic tolerance. We recently identified a novel orally active neuropeptide FF (NPFF) receptor antagonist, RF313, which efficiently prevents the development of fentanyl-induced hyperalgesia in rats. In this study, we investigated the properties of this compound into more details. We show that RF313 exhibited a pronounced selectivity for NPFF receptors, antagonist activity at NPFF1 receptor (NPFF1R) subtype both in vitro and in vivo and no major side effects when administered in mice up to 30 mg/kg. When co-administered with opiates in rats and mice, it improved their analgesic efficacy and prevented the development of long lasting opioid-induced hyperalgesia. Moreover, and in marked contrast with the dipeptidic NPFF receptor antagonist RF9, RF313 displayed negligible affinity and no agonist activity (up to 100 µM) toward the kisspeptin receptor. Finally, in male hamster, RF313 had no effect when administered alone but fully blocked the increase in LH induced by RFRP-3, while RF9 per se induced a significant increase in LH levels which is consistent with its ability to activate kisspeptin receptors. Altogether, our data indicate that RF313 represents an interesting compound for the development of therapeutic tools aiming at improving analgesic action of opiates and reducing adverse side effects associated with their chronic administration. Moreover, its lack of agonist activity at the kisspeptin receptor indicates that RF313 might be considered a better pharmacological tool, when compared to RF9, to examine the regulatory roles of RF-amide-related peptides and NPFF1R in reproduction.
Subject(s)
Analgesics, Opioid/therapeutic use , Hyperalgesia/drug therapy , Narcotic Antagonists/therapeutic use , Oligopeptides/therapeutic use , Receptors, Neuropeptide/antagonists & inhibitors , Administration, Oral , Animals , CHO Cells , Cricetinae , Cricetulus , Disease Models, Animal , Fentanyl/pharmacology , Humans , Male , Mesocricetus , Mice , Mice, Inbred C57BL , Oligopeptides/chemistry , Peptides/therapeutic use , Piperidines/chemistry , Piperidines/therapeutic use , Protein Binding/drug effects , Rats , Rats, Sprague-Dawley , Receptors, Neuropeptide/metabolism , Valine/analogs & derivatives , Valine/chemistry , Valine/therapeutic useABSTRACT
BACKGROUND: Despite numerous pharmacological approaches, there are no common analgesic drugs that produce meaningful relief for the majority of patients with neuropathic pain. Although nitrous oxide (N2O) is a weak analgesic that acts via opioid-dependent mechanisms, it is also an antagonist of the N-methyl-D-aspartate receptor (NMDAR). The NMDAR plays a critical role in the development of pain sensitization induced by nerve injury. OBJECTIVE: Using the chronic constriction injury of the sciatic nerve in male rats as a preclinical model of neuropathic pain, the first aim of the present study was to evaluate the lowest N2O concentration and the shortest time of N2O postinjury exposure that would produce persistent relief of neuropathic pain. The second aim was to compare the effects of N2O with gabapentin, a reference drug used in human neuropathic pain relief. METHODS: Changes in the nociceptive threshold were evaluated using the paw pressure vocalization test in rats. RESULTS: Among the various N2O concentrations tested, which ranged from 25% to 50%, only 50% N2O single exposure for 1 h 15 min induced a persistent (minimum of three weeks) and significant (60%) reduction in pain hypersensitivity. A single gabapentin dose (75 mg/kg to 300 mg/kg, intraperitoneally) induced an acute (1 h to 1 h 30 min) dose-dependent effect, but not a persistent effect such as that observed with N2O. CONCLUSIONS: These preclinical results suggest that N2O is advantageous for long-lasting neuropathic pain relief after sciatic nerve injury compared with other drugs used in humans such as gabapentinoids or NMDAR antagonists. The present preclinical study provides a rationale for developing comparative clinical studies.
Subject(s)
Analgesics/therapeutic use , Hyperalgesia/drug therapy , Neuralgia/drug therapy , Neuralgia/physiopathology , Nitrous Oxide/therapeutic use , Pain Threshold/drug effects , Amines/therapeutic use , Animals , Cyclohexanecarboxylic Acids/therapeutic use , Disease Models, Animal , Dose-Response Relationship, Drug , Gabapentin , Hyperalgesia/etiology , Male , Pain Measurement , Rats , Rats, Sprague-Dawley , Time Factors , Treatment Outcome , gamma-Aminobutyric Acid/therapeutic useABSTRACT
Through the development of a new class of unnatural ornithine derivatives as bioisosteres of arginine, we have designed an orally active peptidomimetic antagonist of neuropeptide FF receptors (NPFFR). Systemic low-dose administration of this compound to rats blocked opioid-induced hyperalgesia, without any apparent side-effects. Interestingly, we also observed that this compound potentiated opioid-induced analgesia. This unnatural ornithine derivative provides a novel therapeutic approach for both improving analgesia and reducing hyperalgesia induced by opioids in patients being treated for chronic pain.
Subject(s)
Analgesics, Opioid/toxicity , Fentanyl/toxicity , Hyperalgesia/chemically induced , Hyperalgesia/prevention & control , Peptidomimetics/therapeutic use , Animals , Arginine/metabolism , Chemical Phenomena , Cyclic AMP/metabolism , HEK293 Cells , Humans , Male , Microsomes, Liver/drug effects , Microsomes, Liver/metabolism , Ornithine/metabolism , Pain Threshold/drug effects , Peptidomimetics/chemistry , Protein Binding/drug effects , Rats , Rats, Sprague-Dawley , Receptors, Neuropeptide/antagonists & inhibitors , Receptors, Neuropeptide/metabolism , Structure-Activity Relationship , Time Factors , Tritium/pharmacokineticsABSTRACT
BACKGROUND: Opioid-induced hyperalgesia (OIH) is a recognized complication of opioid use that may facilitate the development of exaggerated postoperative pain. OBJECTIVE: To examine the role of genetic factors on OIH by comparing four rat strains. Because the authors previously reported that the endogenous opioids released during non-nociceptive environmental stress induce latent pain sensitization, genetic and environmental factor interactions were also evaluated. METHODS: First, the propensity of Sprague Dawley, Wistar, Lewis and Fischer rats to develop OIH following single or repeated fentanyl exposures was compared by measuring the nociceptive threshold using the paw pressure vocalization test. Second, Sprague Dawley and Fischer rats were exposed to a series of three non-nociceptive environmental stress sessions to evaluate the ability of endogenous opioids to enhance hyperalgesia associated with a carrageenan-induced hind-paw inflammation test performed two weeks later. RESULTS: Sprague Dawley, Wistar and Lewis rats exhibited OIH, although differences were observed. OIH was not observed in Fischer rats. Inflammatory hyperalgesia enhancement induced through previous stress in Sprague Dawley rats was not observed in Fischer rats. CONCLUSIONS: The pain level not only reflects nociceptive inputs but also depends on both the history and genetic factors of the individual. Genetic and environmental models may provide new insights into the mechanisms that underlie individual differences observed in postoperative pain.
Subject(s)
Analgesics, Opioid/pharmacology , Fentanyl/pharmacology , Hyperalgesia/physiopathology , Pain Threshold/drug effects , Analgesics, Opioid/metabolism , Animals , Carrageenan/toxicity , Disease Models, Animal , Female , Hyperalgesia/chemically induced , Male , Pain Measurement , Rats , Rats, Inbred F344 , Rats, Sprague-Dawley , Rats, Wistar , Species SpecificityABSTRACT
OBJECTIVES: We set up plasma normetanephrine (pNMA) and metanephrine (pMA) assays as they demonstrated their usefulness for diagnosing phaeochromocytomas. Our scope is to describe some practical laboratory aspects and the clinical relevance of these assays in our endocrinological or cardiological departments. METHODS: We retrospectively reviewed the results of MA from a population of in- and outpatients over a 7-year period. Subjects (n=2536) from endocrinological or cardiological departments were investigated (66 phaeochromocytomas). Urinary NMA (uNMA) and pNMA, and urinary MA (uMA) and pMA were assayed by HPLC with electrochemical detection. RESULTS: pNMA and pMA assays are now more frequently requested than uNMA and uMA. This changed our laboratory work load with improved delivery, sensitivity and reliability of plasma assays as well as reduced apparatus maintenance time. The pNMA and pMA upper reference limits (URLs) of subjects with no phaeochromocytoma were 1040 and 430 pmol/l respectively. Sensitivity and specificity based on receiver operating characteristic curves optimal points were 83 and 93% for pNMA at 972 pmol/l and 67 and 98% for pMA at 638 pmol/l. Sensitivity and specificity of paired tests of pMA (positive test: at least one analyte above its URLs) were 100 and 91% respectively. CONCLUSION: The very low concentration of analytes requires a sustained very good apparatus analytical sensitivity. This can be obtained in an up-to-date laboratory. In terms of clinical performances, assays in plasma or urine are equivalent. Depending on local preferences, populations, strategies or departments, requests for one or the other assay may sustain the need for specifically defined reference ranges.
Subject(s)
Adrenal Gland Neoplasms/blood , Biomarkers, Tumor/blood , Metanephrine/blood , Normetanephrine/blood , Pheochromocytoma/blood , Adolescent , Adult , Aged , Aged, 80 and over , Chromatography, High Pressure Liquid , Cohort Studies , Female , Humans , Male , Middle Aged , ROC Curve , Reproducibility of Results , Retrospective Studies , Sensitivity and Specificity , Young AdultABSTRACT
In humans, hyperalgesia, tolerance and anxiety disorders are common symptoms during heroin withdrawal syndrome. Significant evidence supports a role of NMDA receptors in these phenomena. Because polyamines may positively modulate the functioning of NMDA receptors and mainly originate from dietary intake, one hypothesis is that a polyamine deficient diet (PD diet) may reduce withdrawal symptoms. To address this question, we investigated the ability of a PD diet to prevent or to alleviate some symptoms of withdrawal syndrome as hyperalgesia, and increased anxiety-like behaviour in rats receiving 14 once daily subcutaneous heroin injections. Here, we show that a PD diet has both preventive and curative properties for reducing certain signs of withdrawal such as hyperalgesia, tolerance and increased anxiety-like behaviour observed in rats fed with a standard diet. Moreover, in heroin-withdrawn rats which were returned to basal pain sensitivity level, hyperalgesia following acute analgesia induced by a single heroin dose was observed in heroin-treated rats fed with standard diet, not in rats fed with a PD diet. Similarly, a stress-induced hyperalgesia induced by a non-nociceptive environmental stress session was observed in heroin-treated rats fed with standard diet. In contrast, a stress-induced analgesia was observed in heroin-treated rats fed with a PD diet, as it was observed in non heroin-treated rats. Since a PD diet for several weeks did not induce appreciable side-effects in rats, these preclinical results suggest that a PD diet could be an effective strategy for improving the relief of certain negative emotional states of heroin withdrawal syndrome and to allow reducing other medications generally used, such as opioid maintenance drugs.
Subject(s)
Anxiety/diet therapy , Drug Tolerance , Heroin/adverse effects , Hyperalgesia/diet therapy , Polyamines/therapeutic use , Substance Withdrawal Syndrome/diet therapy , Analgesics, Opioid/adverse effects , Analgesics, Opioid/pharmacology , Animals , Anxiety/complications , Diet , Disease Models, Animal , Heroin/pharmacology , Hyperalgesia/chemically induced , Hyperalgesia/complications , Hyperalgesia/prevention & control , Male , Maze Learning/drug effects , Memory, Short-Term/drug effects , Motor Activity/drug effects , Pain Measurement , Polyamines/administration & dosage , Polyamines/pharmacology , Rats , Rats, Sprague-Dawley , Substance Withdrawal Syndrome/complicationsABSTRACT
Based on our earlier reported neuropeptide FF receptors antagonist (RF9), we carried out an extensive structural exploration of the N-terminus part of the amidated dipeptide Arg-Phe-NH(2) in order to establish a structure-activity relationships (SAR) study towards both NPFF receptor subtypes. This SAR led to the discovery of dipeptides (12, 35) with subnanomolar affinities towards NPFF1 receptor subtype, similar to endogenous ligand NPVF. More particularly, compound 12 exhibited a potent in vivo preventive effect on opioid-induced hyperalgesia at low dose. The significant selectivity of 12 toward NPFF1-R indicates that this receptor subtype may play a critical role in the anti-opioid activity of NPFF-like peptides.
Subject(s)
Dipeptides/pharmacology , Receptors, Neuropeptide/antagonists & inhibitors , Dipeptides/chemical synthesis , Dipeptides/chemistry , Dose-Response Relationship, Drug , Humans , Molecular Structure , Structure-Activity RelationshipABSTRACT
Postoperative negative affects such as anxiety need to be better understood and treated to improve patient recovery. The present study evaluates the effect of a single exposure to a high-dose of opioid (4×100 µg/kg fentanyl injections in 15 min intervals resulting in a total dose of 400 µg/kg), as used for surgery in humans, on anxiety-like behavior (ALB) in rats. First, the level of anxiety was evaluated 24-h after a high-dose of fentanyl using an elevated plus-maze apparatus. Second, the preventive effect of BN2572, a N-methyl-D-aspartate receptor (NMDA-R) antagonist, and 50% nitrous oxide (N(2)O), a gas with NMDA-R antagonist properties, was assessed. A significant increase in ALB was observed in fentanyl-treated rats. Interestingly, fentanyl-induced ALB was prevented by BN2572, suggesting a NMDA-dependant pathway. Fentanyl-induced ALB was also prevented by a single 50% N(2)O exposure. The present study provides evidence that deleterious outcomes of opioid use, referred to as "post-opioid syndrome", include not only pain hypersensitivity as previously described, but also negative affects such as anxiety. Since N(2)O prevents elements of this post-opioid syndrome, we speculate that N(2)O could be a good therapeutic agent to facilitate postoperative rehabilitation.
Subject(s)
Anxiety/chemically induced , Excitatory Amino Acid Antagonists/pharmacology , Fentanyl/therapeutic use , Nitrous Oxide/pharmacology , Receptors, N-Methyl-D-Aspartate/drug effects , Animals , Fentanyl/administration & dosage , Fentanyl/adverse effects , Male , Rats , Rats, Sprague-DawleyABSTRACT
UNLABELLED: Although stress induces analgesia, there is evidence that stressful events may exacerbate pain syndromes. Here, we studied the effects of 1 to 3 prestressful events (days 0, 2, and 7), such as non-nociceptive environmental stress, on inflammatory hyperalgesia induced by a carrageenan injection (day 14) in 1 rat hind paw. Changes in nociceptive threshold were evaluated by the paw pressure vocalization test. The higher the number of stress sessions presented to the rats, the greater was the inflammatory hyperalgesia. Blockade of opioid receptors by naltrexone before each stress inhibited stress-induced analgesia and suppressed the exaggerated inflammatory hyperalgesia. Stressed versus nonstressed animals could be discriminated by their response to a fentanyl ultra-low dose (fULD), that produced hyperalgesia or analgesia, respectively. This pharmacological test permitted the prediction of the pain vulnerability level of prestressed rats because fULD analgesic or hyperalgesic indices were positively correlated with inflammatory hyperalgesic indices (r(2) = .84). In prestressed rats, fULD-induced hyperalgesia and the exaggerated inflammatory hyperalgesia were prevented NMDA receptor antagonists. This study provides some preclinical evidence that pain intensity is not only the result of nociceptive input level but is also dependent on the individual history, especially prior life stress events associated with endogenous opioid release. PERSPECTIVE: Based on these preclinical data, it would be of clinical interest to evaluate whether prior stressful events may also affect further pain sensation in humans. Moreover, this preclinical model could be a good tool for evaluating new therapeutic strategies for relieving pain hypersensitivity.
Subject(s)
Hyperalgesia/etiology , Opioid Peptides/metabolism , Pain Threshold/physiology , Receptors, N-Methyl-D-Aspartate/metabolism , Stress, Psychological/complications , Analgesics, Opioid , Analysis of Variance , Animals , Carrageenan/toxicity , Disease Models, Animal , Excitatory Amino Acid Antagonists/pharmacology , Fentanyl , Inflammation/chemically induced , Inflammation/complications , Ketamine/pharmacology , Male , Naltrexone , Narcotic Antagonists , Pain Measurement , Pain Threshold/drug effects , Rats , Rats, Sprague-Dawley , Swimming/psychology , Time FactorsABSTRACT
Rats received an intraplantar carrageenan injection for inducing hind paw inflammation. After 1 h 45 min, they were exposed to medical air (air group), xenon 25% (Xe-25 group) or 50% (Xe-50 group) for 1 h 45 min. Mechanical nociceptive threshold was evaluated on experimental day and once daily for 1 week. Beyond the well-known antinociceptive effect of xenon, the delayed hyperalgesia observed for 4 days after carrageenan injection was strongly reduced in Xe-25 group and totally suppressed in Xe-50 group on the inflamed hind paw. Moreover, delayed hyperalgesia on the noninflamed hind paw was totally suppressed for both the xenon concentrations. These results show that xenon, beyond its antinociceptive effects, may be a fruitful therapeutic strategy to limit the development of pain sensitization after tissue injury.
Subject(s)
Hyperalgesia/pathology , Hyperalgesia/prevention & control , Inflammation Mediators/pharmacology , Pain/pathology , Pain/prevention & control , Xenon/pharmacology , Afferent Pathways/drug effects , Afferent Pathways/physiology , Anesthetics, Inhalation/pharmacology , Anesthetics, Inhalation/therapeutic use , Animals , Behavior, Animal/drug effects , Behavior, Animal/physiology , Carrageenan/pharmacology , Hyperalgesia/chemically induced , Male , Nociceptors/drug effects , Nociceptors/physiology , Pain/chemically induced , Pain Measurement/drug effects , Pain Measurement/methods , Rats , Rats, Sprague-Dawley , Time Factors , Treatment Outcome , Xenon/therapeutic useABSTRACT
UNLABELLED: Using the rat chronic constriction injury (CCI) pain model, we evaluated whether nitrous oxide (N2O), a gas shown to have potent anti-hyperalgesic properties, may alleviate neuropathic pain. Mechanical nociceptive threshold was estimated using the paw pressure vocalization test. Thermal allodynia was challenged by measuring the struggle latency by immersion of the hind paw in a 10 degrees C water bath. A single 50% N2O exposure for 1 hour, 15 minutes not only induced potent anti-nociception during N2O exposure but also provoked a delayed and sustained reduction (37% to 46%) of pain hypersensitivity of the injured hind paw and abolished pain hypersensitivity of the contralateral uninjured hind paw for at least 1 month. Thermal allodynia was completely prevented by a single N2O exposure. A preadministration of naltrexone, which markedly reduced acute N2O-induced anti-nociception, did not affect the persistent reduction of hyperalgesia. The administration of naltrexone in N2O-treated rats, 1 week after the gas exposure, did not induce any effect. This suggests that the long-lasting effect of N2O was not due to its prior acute analgesic effect and was independent of endogenous opioid systems. These data suggest that 50% N2O exposure could be an efficient and safe strategy for alleviating neuropathic pain in a persistent manner. PERSPECTIVE: Because a single 50% N2O exposure induced a persistent reduction of hyperalgesia-allodynia in a rat neuropathic pain model, clinical trials must be developed for evaluating the N2O effects in patients with neuropathic pain. The ability of N2O to potentiate analgesic effects of other drugs also must be evaluated.
Subject(s)
Analgesics/therapeutic use , Nitrous Oxide/therapeutic use , Pain/drug therapy , Peripheral Nervous System Diseases/complications , Analgesics/administration & dosage , Animals , Disease Models, Animal , Functional Laterality , Male , Naltrexone/therapeutic use , Narcotic Antagonists/therapeutic use , Nitrous Oxide/administration & dosage , Pain/etiology , Pain Measurement , Pain Threshold/drug effects , Physical Stimulation , Random Allocation , Rats , Rats, Sprague-Dawley , Temperature , Time Factors , Treatment OutcomeABSTRACT
BACKGROUND: Tissue damage associated with surgery often produces peripheral and central sensitization that may outlast the stimuli, leading to exaggerated postoperative pain. Paradoxically, the use of opioid analgesia, which is essential for surgical pain management may induce pain sensitization leading to enhanced postoperative pain and an increased risk of developing chronic pain. We studied whether a surgical incision in the rat hindpaw may favor the development of long-term pain vulnerability by estimating hyperalgesia induced by an inflammatory stimulation of the unlesioned contralateral hindpaw 3 wk later. We also evaluated the ability of nefopam, an analgesic drug commonly used in postoperative pain management, to prevent not only exaggerated postoperative pain but also long-term pain vulnerability. The efficacy of morphine was assessed 1 day after surgical incision. METHODS: On Day 0, a surgical plantar incision was performed in one hindpaw of rats treated or untreated with fentanyl (4 x 100 microg/kg, one injection every 15 min). Nefopam (10 mg/kg) or saline was subcutaneously injected 30 min before injury. Three weeks later, once pain measures had returned to basal values, a subsequent nociceptive stimulus, specifically intraplantar carrageenan injection, was performed to evaluate pain sensitivity in incision- and fentanyl-experienced rats. Pain was measured by the paw-pressure vocalization test and the weight bearing test. RESULTS: Surgical incision in rats induced latent and long-term pain hypersensitivity, which was manifested by exaggerated hyperalgesia on carrageenan injection. Administering fentanyl in association with the surgical incision induced exaggerated postoperative pain. When injected before incision, nefopam reduced the exaggerated postoperative pain induced by perioperative fentanyl treatment and prevented the development of long-term pain hypersensitivity. Preoperative nefopam administration also improved morphine analgesic efficacy in the context of fentanyl-induced postoperative hyperalgesia. CONCLUSIONS: Given preemptively, nefopam may be effective at improving postoperative pain management and at reducing the risk of developing postoperative chronic pain, because the drug has both analgesic and antihyperalgesic properties.
Subject(s)
Analgesics, Non-Narcotic/therapeutic use , Hyperalgesia/drug therapy , Nefopam/therapeutic use , Pain, Postoperative/etiology , Pain, Postoperative/prevention & control , Analgesics, Opioid , Animals , Carrageenan , Chronic Disease , Fentanyl , Hyperalgesia/chemically induced , Male , Pain/chemically induced , Pain/prevention & control , Pain Measurement/drug effects , Rats , Rats, Sprague-DawleyABSTRACT
PURPOSE: Opioids are widely used for anesthesia but paradoxically induce postoperative pain hypersensitivity via N-methyl-D: -aspartate (NMDA) receptor modulation. Sevoflurane effects on opioid-induced hyperalgesia have not been yet evaluated in vivo. Nevertheless, some experimental in vitro studies reported anti-NMDA receptor properties for sevoflurane. The aim of this study was to evaluate sevoflurane effects on fentanyl-induced hyperalgesia in opioid-naive rats and in rats with inflammatory pain. METHODS: Sevoflurane effects on hyperalgesia were evaluated in Sprague-Dawley rats: opioid-naive rats, rats treated with fentanyl (4 x 60 microg kg(-1)) and rats with inflammatory pain (carrageenan) treated with fentanyl (4 x 60 microg kg(-1)). On day zero, subcutaneous fentanyl injections were administered and inflammatory pain was induced with one carrageenan injection in one hind paw. Rats were exposed to low concentrations of sevoflurane (1.0 or 1.5%) on day zero prior to fentanyl injections and inflammatory pain induction, and for the duration of the fentanyl analgesic effect. The nociceptive threshold (Randall-Selitto test) was evaluated daily for 7 days. On day seven, naloxone was injected and the nociceptive threshold was assessed 5 min later. RESULTS: In rats without inflammatory pain but treated with fentanyl on day zero, sevoflurane 1.0% reversed the early (day zero) and long-lasting (day zero to day three) hyperalgesia classically described after high-doses of fentanyl (P < 0.05). This sevoflurane concentration antagonized the hyperalgesia induced by naloxone on day seven (P = 0.33). In a second experiment in rats with inflammatory pain, exposure to low concentrations of sevoflurane (1.0 and 1.5%) did not reduce fentanyl-induced hyperalgesia (P > 0.05), but nevertheless antagonized the naloxone induced hyperalgesia on day seven (P = 0.061). CONCLUSION: Relatively low sevoflurane concentrations (1.0%) reverse fentanyl-induced hyperalgesia in rats without inflammatory pain. Nevertheless, the lack of effect of sevoflurane concentrations of 1.0% and 1.5% to oppose hyperalgesia following high-dose fentanyl and inflammatory pain suggests that sevoflurane anti-hyperalgesic properties are weak.
Subject(s)
Analgesics, Opioid/toxicity , Fentanyl/toxicity , Hyperalgesia/drug therapy , Methyl Ethers/pharmacology , Anesthetics, Inhalation/administration & dosage , Anesthetics, Inhalation/pharmacology , Animals , Carrageenan/toxicity , Disease Models, Animal , Dose-Response Relationship, Drug , Hyperalgesia/chemically induced , Male , Methyl Ethers/administration & dosage , Naloxone/pharmacology , Narcotic Antagonists/pharmacology , Pain Measurement , Rats , Rats, Sprague-Dawley , Receptors, N-Methyl-D-Aspartate/drug effects , Receptors, N-Methyl-D-Aspartate/metabolism , SevofluraneABSTRACT
The present study aimed to examine the effects of an acute administration of the mu-opioid receptor fentanyl on affect as assessed by place-conditioning procedure in rats. We determined the affective properties of fentanyl not only immediately following its administration, but also 24h later. Experiments were performed using the dose of fentanyl (240 gamma/kg; four injections of 60 gamma/(ml kg) every 15 min, subcutaneously) for which secondary hyperalgesia has been previously described. Our results show that the acute administration of fentanyl display biphasic affective properties, with early rewarding and 24-h delayed aversive components. The 24-h delayed aversive effects of fentanyl were not observed in animals submitted to a polyamine-deficient diet, suggesting an NMDA-dependent mechanism.
Subject(s)
Amines/metabolism , Analgesics, Opioid/administration & dosage , Conditioning, Operant/drug effects , Deficiency Diseases/prevention & control , Fentanyl/administration & dosage , Animals , Behavior, Animal/drug effects , Dose-Response Relationship, Drug , Drug Administration Schedule , Male , Rats , Rats, Long-Evans , Reward , Spatial Behavior/drug effects , Time FactorsABSTRACT
There is a compelling body of evidence that N-methyl-d-aspartate receptors (NMDA-R) play a critical role in the development and maintenance of pain hypersensitivity. However, long-term treatments with NMDA-R antagonists are limited by unacceptable side effects. Since polyamines modulate the functioning of NMDA-R and mainly originate from normal dietary intake and bacterial metabolism in the gut, we developed a nutritional therapy based on dietary polyamine deficiency. Here, we reported that a polyamine deficient diet (PD diet) for 7 days prevented the enhancement of tyrosine phosphorylation of the spinal NR2B subunit-containing NMDA-R associated with inflammation in rats. Based on these data, we studied the ability of PD diet to prevent long-lasting pain hypersensitivity associated with tissue injury on one hind paw by evaluating long-lasting changes in both mechanical nociceptive threshold and weight bearing. A PD diet strongly reduced long-lasting hyperalgesia induced by inflammation or incision, especially in fentanyl-treated rats. Moreover a PD diet also prevented the exaggerated hyperalgesia induced by a second inflammation performed 7 days after the first one. A PD diet also opposed paradoxical hyperalgesia induced by non-nociceptive environmental stress in rats with pain and opioid experiences. A PD diet reversed pain hypersensitivity associated with monoarthritis or neuropathy and restored the analgesic effect of morphine. Since PD diet was devoid of any noticeable side effects, this nutritional therapy could be part of an effective and safe strategy for pre-emptive analgesia and for reducing the transition from acute to chronic pain and its outcomes in various pain syndromes.